http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CytoSorbents to Report Q1 2021 Operating and Financial Results
-
U.S. FDA Approves CytoSorbents (CTSO) to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery
-
U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery
-
CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey
-
Cytosorbents (CTSO) Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery
-
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery
-
CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference
-
CytoSorbents Announces 2020 Financial and Operational Results
-
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
-
CytoSorbents to Report Fiscal 2020 Operating and Financial Results
-
CytoSorbents to Present at the Cowen 41st Annual Health Care Conference
-
CytoSorbents 2021: Leadership and Growth in the "New Normal"
-
CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference
-
National Institute for Health and Care Excellence (NICE) Issues Medtech Innovation Briefing on CytoSorb for Reducing Risk of Bleeding During Cardiac Surgery
-
CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President - Global Regulatory Affairs
-
Cytosorbents (CTSO) Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care
-
CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care
-
Cytosorbents (CTSO) Announces Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
-
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
-
CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue
-
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
-
Cytosorbents (CTSO) Announces Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
-
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
-
CytoSorbents Promotes Dr. Christian Steiner to Executive Vice President of Sales and Marketing
-
CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank
-
Cytosorbents (CTSO) Announces Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock Study
-
Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock Study
-
CytoSorbents Launches International Campaign to Raise $100,000 for the Global Humanitarian Organization, CARE
-
Cytosorbents (CTSO) Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients
-
CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients
-
CytoSorbents to Present at the Piper Sandler 32nd Annual Healthcare Conference
-
CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference
-
CytoSorbents Reports Record Third Quarter 2020 Financial Results
-
CytoSorbents to Report Q3 2020 Operating and Financial Results
-
Cytosorbents (CTSO) and Aferetica Announce European Union Approval of PerLife System and ECOS-300CY PerSorb™ Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transplant
-
CytoSorbents and Aferetica Announce European Union Approval of the PerLife™ System and ECOS-300CY™ PerSorb™ Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transpl
-
Cytosorbents (CTSO) Secures $1.1M in Defense Awards to Optimize Development of HemoDefend-BGA for Life-saving Universal Plasma
-
The U.S. Department of Defense Awards $1.1 Million to CytoSorbents to Optimize Development of HemoDefend-BGA™ for Life-saving Universal Plasma
-
Cytosorbents (CTSO) Annunces CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions
-
CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions
-
CytoSorbents Highlights CytoSorb Use in Sepsis Patients During Sepsis Awareness Month and World Sepsis Day 2020
-
CytoSorbents Announces the "CytoSorb Therapy in COVID-19 ICU Patients" (CTC) Registry Is Actively Enrolling
-
Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19
-
Cytosorbents (CTSO) Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb in the U.S. Northeast, Mid-Atlantic, and Florida under FDA EUA for COVID-19
-
CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19
-
CytoSorbents Reports Record Second Quarter 2020 Financial Results
-
CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date
-
Cytosorbents (CTSO) Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
-
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
-
Cytosorbents (CTSO) Reports REFRESH 2-AKI Trial Data Monitoring Committee has Recommended Study Resumption Following Favorable Review of Safety Data

